Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study groupDominik Paul Modest, Anke Reinacher‐Schick, Sebastian Stintzing et al.|Annals of Oncology|2016Cited by 344
Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische OnkologieSylvie Lorenzen, Florian Lordick, Tibor Schuster et al.|Annals of Oncology|2009Cited by 241
<i>TFAP2E–DKK4</i> and Chemoresistance in Colorectal CancerMatthias Ebert, Roland M. Schmid, Marc Tänzer et al.|New England Journal of Medicine|2012Cited by 184